💊 Pharma Bro's Woes
Infamous Pharma Bro Martin Shkreli can never work in the pharmaceutical industry again. So said a federal judge in ruling last week. Shkreli, who remains in prison for securities fraud, was also ordered to repay upwards of $64 million in profits he made off raising the price of the drug Daraprim over 5400%.
“Banning an individual from an entire industry and limiting his future capacity to make a living in that field is a serious remedy and must be done with care and only if equity demands,” US district judge Denise Cote wrote in his ruling, notes The Guardian.
Kevin Mulleady, then-CEO of Daraprim's maker Vyera, has settled to not work in the pharmaceutical industry for 7 years, and will face a $250,000 if he does, according to NPR.
No Bail Over Bounty
During the 2016 presidential race, Hillary Clinton singled Shkreli out for his crimes, which then led the disgraced hedge fund manager to call for a bounty on a "follicle" of her hair. Shkreli posted to Facebook “$5,000 but the hair has to include a follicle. Do not assault anyone for any reason ever (LOLIBERALS).” The post was later deleted, but Shkreli lost bail as a result.
Shkreli has always been an easy scapegoat for issues way beyond himself, however, it doesn't appear the rest of the pharmaceutical industry or any big money investors are paying attention to his fate.